SCHEMBL446361

SCHEMBL446361

Clc1ccnn2ccnc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMPD3 Q9NY59 3/20 0.38
AXL P30530 1/20 0.38
ADRA1D P25100 1/20 0.37
ADRA1A P35348 1/20 0.37
ADRA1B P35368 1/20 0.37
CDK2 P24941 2/20 0.35
CCNE2 O96020 1/20 0.35
CCNE1 P24864 1/20 0.35
KDM4E B2RXH2 1/20 0.35
PKM P14618 1/20 0.35
HSD17B10 Q99714 1/20 0.35
JAK2 O60674 2/20 0.35
JAK1 P23458 2/20 0.35
TYK2 P29597 2/20 0.35
JAK3 P52333 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
NLRP3 Q96P20 1/20 0.33
BMP4 P12644 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14699684 0.74 SMPD3 (0.57) SMPD3AXLCDK2BMP4NUDT1
SCHEMBL9124027 0.74 SMPD3 (0.39) SMPD3AXLCDK2KDM4ESMN1; SMN2
SCHEMBL4569294 0.74 SMPD3 (0.38) SMPD3AXLCDK2KDM4EHSD17B10
SCHEMBL3122125 0.74 SMPD3 (0.38) SMPD3AXLCDK2JAK1BMP4
SCHEMBL9935120 0.74 SMPD3 (0.38) SMPD3AXLCDK2JAK1BMP4
SCHEMBL10437263 0.72 SMPD3 (0.41) SMPD3AXLCDK2KDM4EPKM
Hydrochloric Acid SCHEMBL31619326 0.72 SMPD3 (0.38) SMPD3AXLCDK2KDM4ESMN1; SMN2
Hydrochloric Acid SCHEMBL3702394 0.72 SMPD3 (0.37) SMPD3AXLCDK2KDM4EHSD17B10
SCHEMBL1507164 0.70 NUDT1 (0.45) ADRA1DADRA1AADRA1BCDK2CCNE2
SCHEMBL179552 0.70 PDE10A (0.38) SMPD3AXLCDK2KDM4ENUDT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435091-B2 RNA-binding protein multimerization inhibitors and methods of use thereof THE UAB RESEARCH FOUNDATION (US) 2025-10-07 US disclosed
US-20230159542-A1 RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF THE UAB RESEARCH FOUNDATION (US) 2023-05-25 US disclosed
WO-2021216757-A1 RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF THE UAB RESEARCH FOUNDATION (US) 2021-10-28 WO disclosed
EP-2300469-B1 FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS NOVARTIS AG (CH) 2015-06-24 EP disclosed
US-8637516-B2 Compounds and compositions as TRK inhibitors IRM LLC (BM) 2014-01-28 US disclosed
US-8507488-B2 Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors IRM LLC (BM) 2013-08-13 US disclosed
EP-2614062-A1 IMIDAZO [1, 2]PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS IRM LLC (BM) 2013-07-17 EP disclosed
US-20120065184-A1 COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS IRM LLC (BM) 2012-03-15 US disclosed
WO-2012034091-A1 IMIDAZO [1, 2] PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS IRM LLC (BM) 2012-03-15 WO disclosed
EP-2350075-A1 SUBSTITUTED IMIDAZOÝ1,2B¨PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS Array Biopharma, Inc. (US) 2011-08-03 EP disclosed
US-20110166133-A1 FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS IRM LLC (BM) 2011-07-07 US disclosed
EP-2300469-A2 FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS IRM LLC (BM) 2011-03-30 EP disclosed
WO-2010033941-A1 SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-03-25 WO disclosed
WO-2009140128-A2 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2009-11-19 WO disclosed
EP-0381132-A1 Imidazopyridazines, their production and use Takeda Chemical Industries, Ltd. (JP) 1990-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166133-A1 FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS ALK, ROS1, FLT3 SMPD3 2500/4885AXL 59/4885ADRA1D 4183/4885
US-20120065184-A1 COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS TNK2, CNKSR1, BMP2K SMPD3 2489/4885AXL 1862/4885ADRA1D 3241/4885
US-20230159542-A1 RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF HNRNPR, HNRNPAB, RBM3 SMPD3 3981/4885AXL 3474/4885ADRA1D 4544/4885
US-12435091-B2 RNA-binding protein multimerization inhibitors and methods of use thereof HNRNPR, HNRNPAB, RBM3 SMPD3 3981/4885AXL 3474/4885ADRA1D 4544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.